EUVIMEDEUVIMED entdecken
Crossref

CMTM6: a potential biomarker in non-small cell lung carcinoma

Seda Tas Ayçiçek, Sıddıka Fındık

Polish Journal of Pathology · 23.02.2026 · 76 (4) · 307-317

DOI: 10.5114/pjp.2025.159328 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Polish Journal of Pathology, online erschienen am 23.02.2026. Verfasst von Seda Tas Ayçiçek und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Meram State Hospital, Konya, Turkey. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, MARVEL Domain-Containing Proteins. Die Arbeit nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung cancer is the most common cause of cancer-related deaths worldwide. With the advent of immunotherapy, programmed cell death-1 and programmed death ligand 1 (PD-L1) inhibitors have gained clinical importance, driving research into their regulatory mechanisms. CKLF-like MARVEL transmembrane domain- containing 6 (CMTM6) has been identified as a key regulator of PD-L1. In our study, we aimed to assess the prognostic significance of PD-L1 and CMTM6 expression in patients with non-small cell lung carcinoma (NSCLC).

This study included 100 patients with NSCLC. CMTM6 and PD-L1 expression were evaluated using immunohistochemistry, and H-scores were calculated.

A positive correlation was observed between H-PD-L1 and H-CMTM6 scores. In addition, both immunohistochemical scores were positively correlated with tumor size and grade. Both H-PD-L1 and H-CMTM6 scores of patients with adenocarcinoma were found to be lower than those of squamous carcinoma and other carcinoma types. Non-mucinous adenocarcinomas were grouped according to their predominant pattern (Group 1: lepidic pattern, Group 2: acinar and papillary pattern, Group 3: solid, micropapillary, and complex glandular/cribriform pattern). Group 3 had higher H-PD-L1 and H-CMTM6 scores than the others.

Our study demonstrated a correlation between CMTM6 and PD-L1 in NSCLC and suggested that CMTM6 may serve as a potential adverse prognostic marker.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsMARVEL Domain-Containing ProteinsBiomarkers, TumorB7-H1 AntigenPrognosisHumansMaleFemaleAdultMiddle AgedAgedAged, 80 and overImmunohistochemistryMyelin Proteins

Stichwörter der Autor:innen

CMTM6non-small cell lung carcinoma (NSCLC).prognosisPD-L1

Substanzen

Biomarkers, TumorCMTM6 protein, humanMARVEL Domain-Containing ProteinsCD274 protein, humanB7-H1 AntigenMyelin Proteins

Autor:innen und Institutionen

  • Department of Pathology, Meram State Hospital, Konya, Turkey.
  • Department of Pathology, Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey.

Zitieren

APA

Ayçiçek, S. T., & Fındık, S. (2026). CMTM6: a potential biomarker in non-small cell lung carcinoma. Polish Journal of Pathology, 76(4), 307-317. https://doi.org/10.5114/pjp.2025.159328

Vancouver

Ayçiçek ST, Fındık S. CMTM6: a potential biomarker in non-small cell lung carcinoma. Polish Journal of Pathology. 2026;76(4):307-317. doi:10.5114/pjp.2025.159328

BibTeX
@article{Ayiek2026,
  author = {Ayçiçek, Seda Tas and Fındık, Sıddıka},
  title = {CMTM6: a potential biomarker in non-small cell lung carcinoma},
  journal = {Polish Journal of Pathology},
  year = {2026},
  volume = {76},
  number = {4},
  pages = {307--317},
  doi = {10.5114/pjp.2025.159328}
}
Kostenlos starten →